SKB105 for Injection in Advanced Solid Tumors

计划入组 256 人 · 首次发布于 2026 年 2 月 2 日

SKB103 for Injection in Advanced Solid Tumors

计划入组 277 人 · 首次发布于 2026 年 3 月 10 日

Study of SKB103 in HER2-negative Breast Cancer

计划入组 140 人 · 首次发布于 2026 年 8 月 19 日

KB105

SK2005

NIB105

Kelun-Biotech and Crescent Biopharma Form Strategic Partnership to Advance Novel Oncology Therapeutics

Kelun-Biotech Achieves Breakthrough in First-Line NSCLC Treatment with World's First Successful ADC-Immunotherapy Combination

Global Pharma Companies Seek R&D Efficiency Lessons from China's Clinical Trial Success